Affinity maturation of the immune response and the generation of long-lived bone marrow (BM) plasma cells are hallmarks of CD40-dependent, thymus-dependent (TD) humoral immunity.Through disruption of the tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6)-binding site within the CD40 cytoplasmic domain, we selectively ablated affinity maturation and the generation of plasma cells after immunization. Mutagenesis of both the TRAF6 and TRAF2-TRAF3 sites was essential for arresting germinal center formation in response to immunization. CD40-induced B cell proliferation and early immunoglobulin production occurred even when all TRAF sites were ablated. These studies show that specific CD40-TRAF associations control well defined aspects of humoral immunity. In addition, they define the roles that TRAF-dependent and TRAF-independent pathways play in regulating antigen-driven B cell differentiation.
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells
Binding of CD40 ligand (CD40L, also known as CD154), which is expressed on activated helper T lymphocytes, to its receptor CD40, which is expressed on B lymphocytes, is essential for thymus-dependent (TD) humoral immunity. CD40 engagement triggers clonal B cell expansion, germinal center (GC) formation, production of memory B cells, antibody isotype switching, affinity maturation and the generation of long-lived plasma cells 1 . Oligomerization of CD40 by CD154 induces cytoplasmic signaling via recruitment of tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) 1, 2, 3, 5 and 6 to specific domains in the CD40 cytoplasmic tail [2] [3] [4] . These adapter molecules, which have no intrinsic enzymatic activities, are believed to activate Ser and Thr kinases, which can then couple the receptor complex to downstream mitogen-activated protein kinase (MAPK) and IκB kinase cascades. Although studies are beginning to resolve how TRAFs act as adapters to canonical signaling pathways following CD40 engagement, none have determined which TRAFs are involved in controlling the complex process of antigen-driven B cell differentiation in vivo.
One means with which to study TRAF function in vivo has been to genetically delete specific TRAF genes in mice. However, mice deficient in TRAF2, TRAF3 or TRAF6 suffer from profound developmental insufficiencies that compromise their use in studies of CD40 function in immunity [5] [6] [7] . Interpretation of data obtained with these mice is further confounded by the fact that TRAFs act as signaltransduction elements for a number of TNFR family and cytokine receptors 8 . Nonetheless, in vitro studies have shown that B cells from TRAF2-and TRAF6-deficient mice show defects in CD40-induced NF-κB signaling and proliferation 6, 7, 9, 10 . An alternative strategy for evaluating the function of TRAF proteins in CD40-induced B cell differentiation has been to selectively mutagenize well defined TRAF-binding sites in the cytoplasmic tail of CD40. Published studies have confirmed the identity of the TRAF2 and TRAF 3 (TRAF2/3)-and the TRAF6-binding sites 3, 11, 12 . With the use of B cell lines, site-directed mutagenesis of the TRAF2/3-binding site has shown that this site is important for the induction of c-Jun NH2-terminal kinase (Jnk), NF-κB and certain differentiation functions, including the upregulation of costimulatory molecules and the induction of immunoglobulin (Ig) germline heavy chain transcripts [13] [14] [15] . Mutagenesis of the TRAF6 site has suggested that this domain may also be involved with the induction of Ig germline transcription; however, it is not clear which downstream kinase cascades are activated by TRAF6 recruitment to the CD40 receptor complex 4, 12, 14 . Adopting the approach described above, we produced transgenic mice that expressed mutant CD40 receptors (X-CD40) in which specific TRAF-binding sites were disrupted. Each of the X-CD40 lines were tested for their ability to propagate a CD40 signal and to develop humoral immune responses upon immunization. Analysis of primary and secondary humoral immune responses in these mice allowed us to define the TRAF-dependent and -independent components of antigen- 
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based on previous studies in TRAF-deficient mice, we found that loss of TRAF recruitment imparts specific and well defined deficiencies in the development of humoral immunity.
Results

Generation of transgenic X-CD40-expressing mice
The function of TRAF proteins in CD40-dependent humoral immunity was evaluated in a cohort of transgenic mice that expressed mutant CD40 receptors in which specific TRAF-binding sites were disrupted. A chimeric CD40 transgene (generically termed X-CD40) was engineered in which the murine transmembrane and cytoplasmic domains were fused to the extracellular domain of human CD40 and expressed in antigen-presenting cells under the control of the I-Eα promoter 16 . The human-murine chimeric CD40 molecule was engineered because experiments in vitro suggested that homologous interactions between the murine cytoplasmic domain and murine signaling elements were superior to human CD40 in transducing signals in murine cells (unpublished data). This may be due to substantial sequence divergence between murine and human CD40 in the TRAF6-binding site and membrane-proximal regions of the CD40 tail. We chose to use the human extracellular domain so that selective signaling through the chimeric transgenic receptor could be compared to signaling through endogenous murine CD40. Because murine CD154 binds to human CD40 and signals via this molecule 17 , we anticipated that the X-CD40 transgenic receptor would function normally in vivo.
Disruption of TRAF binding to the CD40 cytoplasmic tail was accomplished by site-directed mutagenesis, as described 15 . A mutation was introduced into the cytoplasmic domain that disrupted the binding site for TRAF2 and TRAF3 (Thr   255   →Ala   255 , which is referred to hereafter as ∆T2,3, see Fig. 1 ). Mutation at this site also resulted in the loss of TRAF1 and TRAF5 from the receptor complex, as they associate with TRAF2 and TRAF3 3 . In another construct, mutations were introduced that disrupted the binding site for TRAF6 within the CD40 cytoplasmic domain (Pro , referred to hereafter as ∆T6). Finally, mice were produced that expressed X-CD40 with mutations in both the TRAF2/3 and TRAF6 sites (referred to hereafter as ∆T2, 3, 6) . The ∆T2,3,6 mutant CD40 was unable to bind any of the known TRAFs in vitro or in HEK293 cells 4 . Expression of the X-CD40 transgenes on B cells varied between the different X-CD40-transgenic founder lines used (Fig. 1) . Chimeric CD40 expression on other major histocompatibility complex (MHC) class II-bearing cells from each of the X-CD40 mice showed expression of the transgene on dendritic cells (DCs) and MHC class II-bearing cells (Web Fig. 1 online) .
Ex vivo studies in B cells from X-CD40 mice
CD154 binding to CD40 on B cells activates the Ikβ kinase (IKK) and MAPK pathways. In vitro studies in B cell lines, as well as studies that used TRAF-deficient primary B cells, have linked TRAF2 and TRAF6 to specific downstream signaling cascades 4, 6, 15, 18, 19 . The impact of TRAF-binding site mutations on CD40 signaling has not been 452 Fig. 2a-d) . Splenic B cells from each of the transgenic lines were isolated and selectively triggered through transgenically expressed X-CD40. All the signaling studies were performed on X-CD40 B cells from mice that were crossed onto the CD40 -/-background, so the only CD40 expressed was the X-CD40 transgene. Soluble human CD154 (shCD154) induced NF-κB, Jnk and p38 activation in B cells from the WT X-CD40 mice. The ∆T2,3 mutation prohibited X-CD40-driven phosphorylation of Jnk and p38 (Fig. 2a,b) . These results were identical to those data obtained from murine B cell lines in which Jnk activation was prevented by the ∆T2,3 mutation and from B cells in mice that expressed dominant-negative TRAF2 19, 20 . CD40-mediated activation of NF-κB was measured by phosphorylation of the inhibitory subunit IκBα. Loss of TRAF2/3 recruitment did not completely ablate signaling by this pathway, but rather it imparted a delayed and diminished response (Fig. 2c) . No distinguishable effect on NF-κB, Jnk or p38 was observed in cells that contained the ∆T6 mutant X-CD40. Finally, even in the absence of TRAF recruitment-as observed in ∆T2,3,6 mutant mice-phosphorylation of IκBα was apparent, although the kinetics were delayed and the response diminished. Using B cells from each of the X-CD40 mice on the CD40 +/+ background, we found that signaling via endogenous murine CD40 appeared normal for all the lines (Web Fig. 2 ). In addition, signaling studies that used limiting concentrations of shCD154 resulted in similar patterns of phosphorylation (data not shown).
Engagement of CD40 on ex vivo B cells induces up-regulation of surface molecules, proliferation and immunoglobulin (Ig) secretion 1 . To assess the role played by TRAFs in these CD40-induced responses, B cells from each of the X-CD40 mice were isolated and activated in vitro. In the presence or absence of TRAF recruitment, up-regulation of the B cell activation marker CD23 was observed in all X-CD40 mutants (Fig. 3a) . No alterations in the up-regulation of surface molecules could be attributed to any given mutation. Similar results were seen with the up-regulation of CD80, CD86, CD95 and CD54 (data not shown). In addition, the evaluation of each of these mutations on CD40-induced B cell proliferation in vitro demonstrated no dependence on TRAF recruitment ( Fig. 3b and Web Fig. 3 ). Analysis of cell division with the use of carboxy-fluorescein succinimide ester (CFSE) dilution confirmed that after 4 days of stimulation with CD154, B cells from each X-CD40 mouse line had undergone the same number of cell divisions (data not shown). CD40 and cytokineinduced production of IgM and IgG1 in vitro were similarly unaffected by the lack of TRAF recruitment (Fig. 3c,d ). These data show that the early biological responses of B cells to CD40 engagement in vitro are TRAF-independent.
Humoral immune responses in X-CD40 mice
Mice that are genetically deficient in CD40 or CD154 as well as mice treated with blocking antibody to CD154 do not develop TD humoral immune responses [21] [22] [23] . All X-CD40 mice were immunized with nitrophenol-conjugated keyhole limpet hemocyanin (NP-KLH) in complete Freund's adjuvant (CFA), and early IgG1 responses were monitored (Fig. 4a) . Immunization with NP-KLH allowed us to readily detect . Serum NP-specific IgG1 titers were observed for 60 days after immunization in the absence of TRAF recruitment (that is, in the ∆T2,3,6 mice), albeit in reduced amounts (Fig. 4b) . In contrast to total anti-NP IgG1, the production of high-affinity NP-specific IgG1-as measured on day 68 after immunization-was reduced by >95% in the ∆T6 and ∆T2,3,6 mice. These data suggest an essential role played by TRAF6 in Ig affinity maturation.
Plasma cell differentiation in X-CD40 mice
The terminal differentiation of B cells to plasma cells is a hallmark of TD humoral immune responses. To investigate the role played by TRAFs in triggering terminal B cell differentiation to plasma cells, the number of antibody-secreting cells in the bone marrow of X-CD40 mice 68 days after immunization was determined. In the ∆T6 and ∆T2,3,6 mice, there was a >95% reduction in the number of total plasma cells and high-affinity plasma cells in the bone marrows of immune mice (Fig. 5) . These data indicate that the loss of TRAF6 recruitment, but not TRAF2/3 recruitment, abrogated the generation of long-lived bone marrow plasma cells that secrete either low-or high-affinity NP-specific antibodies.
The generation of memory B cells in the X-CD40 mice was also evaluated by the adoptive transfer of primed X-CD40 B cells into T cell-primed recipients, which was followed by antigen challenge.
Because the ∆T6 mutation impaired affinity maturation, tracking memory B cell responses in recipient mice was problematic. Nonetheless, mice that received B cells from the WT and ∆T2,3 mice, but not the ∆T6 mice, produced high-affinity responses upon challenge (data not shown). Although little can be said with regard to the involvement of TRAF6, TRAF2/3 recruitment was not involved in the generation of memory B cells.
GC formation in X-CD40 mice
GCs are the site of development for TD humoral immune responses, B cell memory and affinity maturation. These processes are dependent on CD40 signaling. To determine whether GC formation was TRAFdependent, X-CD40 mice were immunized with sheep erythrocytes and GC formation was assessed. Confocal microscopy revealed GCs by immunohistological analysis with the use of a GC-specific marker, peanut agglutinin (PNA). GC B cells (which were PNA + CD19 + ) were present in the WT, ∆T2,3 and ∆T6 mice, but not in the ∆T2,3,6 mice (Fig. 6a) . Similarly, flow cytofluorometric analysis revealed GC B cells as PNA + GL7 + B cells. All X-CD40 mice expressed this GC population except for those with the ∆T2,3,6 mutations (Fig. 6b) . Therefore, GC formation in response to immunization is triggered by the recruitment of TRAF2/3 or TRAF6 to the CD40 cytoplasmic domain but cannot occur in the absence of all TRAF recruitment.
Discussion
The TRAF-binding sites of the CD40 cytoplasmic tail have been implicated as key functional components in CD40 signal transduction. Disruption of TRAF binding by site-directed mutagenesis resulted in specific humoral immune deficiencies in transgenic mice. The data we have presented here establish that CD40-induced B cell growth, up-regulation of surface molecules and early Ig production are not dependent on the recruitment of TRAFs to the cytoplasmic domain of CD40. Later events in the humoral immune response, like GC formation, are dependent on the binding of either TRAF2/3 or TRAF6. Finally, the generation of high-affinity antibody and the generation of long-lived, bone marrow plasma cells specifically require recruitment of TRAF6 to the CD40 cytoplasmic domain. The roles played by TRAF molecules as intermediaries in the CD40 signaling cascade have been examined with the use of several independent approaches. The Thr 255 residue (target of the ∆T2,3 mutation) was recognized as a critical functional site in CD40 signaling more than 12 years ago 25 ; later it was shown to be essential for the direct binding of TRAF2 and TRAF3 to CD40 5, 26 . Because TRAF1 and TRAF5 bind indirectly to TRAF2/3 12, 27 , the Thr 255 →Ala 255 mutation also limits their recruitment to CD40. CD40 mutants expressed in B cell lines have confirmed the importance of the TRAF2/3 site in CD40 signaling and transducing biological responses [12] [13] [14] [15] 28, 29 . As an alternative to disrupting TRAF-binding sites, studies have shown that deletion of the genes encoding TRAFs can exert profound effects on CD40 signaling and biology as well. Specifically, B cells from TRAF2 -/-mice show reduced amounts of CD40-induced B cell activation of NF-κB, proliferation and IgG1 production in vivo in response to viral challenge 18 . Based on these studies, a conspicuous functional phenotype in the ∆T2,3 mice was anticipated. The loss of CD40-induced Jnk activation and reduced NF-κB activation in B cells from ∆T2,3 mice that we observed confirmed the anticipated signaling phenotype of the Thr 255 →Ala 255 mutation as well as that observed in TRAF2 dominant-negative mice.However, the loss of TRAF2/3 (and TRAF1 and TRAF5) recruitment appeared to impart no overt deficiency in humoral immunity in vivo, except in the absence of TRAF6 recruitment, where GC formation was lost. Given that the ∆T2,3 mice manifest a moderate phenotype one must consider the possibility that the severe developmental deficiencies in the TRAF2 4 . Disruption of this site ablates p38 activation and represses NF-κB activation via CD40 in HEK293 cells, but not in B cell lines 4, 11, 15 ; this shows that the signaling role played by TRAF6 may be cell-type specific. Unlike the ∆T2,3 mice, the ∆T6 mice showed no abnormality in CD40 signaling in B cells, but demonstrated substantial defects in the development of late-phase humoral immunity. The data collectively suggest that TRAF6 recruitment may play no role during the activation of naïve B cells, but may play a key role within the GC. It is possible that CD40 engagement and TRAF6 recruitment may signal through factors yet to be identified that promote affinity maturation and B cell differentiation within GC cells. This hypothesis is consistent with the observation that the loss of TRAF6 binding in naïve B cells ex vivo has no effect and the observation that as antigen-activated B cells enter the GC, CD40 is "rewired" to support rescue from Iginduced apoptosis 30 . Another key finding to emerge from these studies is the extent to which B cell responses can proceed in the absence of TRAF recruitment. Data from the ∆T2,3,6 mice showed that CD40-induced NF-κB activation, B cell proliferation, up-regulation of surface molecules and early Ig production occur in the absence of TRAF recruitment. As with the X-CD40 mice, studies that used B cell lines have shown that some CD40-induced events are TRAF-independent 14, 15 . Presently, the identity of the non-TRAF signaling intermediaries are unknown. However, non-TRAF-binding domains are present in the cytoplasmic domain of CD40 13, 31 that can activate NF-κB and perhaps trigger cellular activation.
With the use of a similar strategy, another group has evaluated the contribution made by CD40 functional domains through the transgenic expression of truncated or site-mutated full-length human CD40 molecules expressed with an Ig promoter 32 . After crossing onto a CD40 -/-background, these mice expressed the human CD40 transgene only in B cells. They found that CD40 triggering induced B cell proliferation, up-regulation of surface molecules and Ig secretion in vitro in the absence of TRAF recruitment 32 , which was confirmed by the data we obtained with the ∆T2,3,6 mice. They also showed that truncation of the entire cytoplasmic domain ablated these early events, which provides conclusive evidence that non-TRAF-binding domains within the cytoplasmic domain of CD40 are critical for inducing early events. In contrast to the data we obtained with the ∆T2,3 mice, the T 254 →A 254 mice the other group produced showed reduced GC formation and high-affinity antibody production 32 . Although the reason for these differences remains unresolved, one apparent difference between the studies is the expression of CD40 exclusively in B cells versus all MHC class II-bearing cells. Another issue concerns whether the human cytoplasmic domain is as efficient at recruiting and signaling in murine cells as the murine cytoplasmic domain, due to the sequence differences in and around the TRAF6-binding site. Although some discrepancies exist within the data, taken together these two studies have defined the roles played by TRAF molecules in controlling humoral immunity.
In summary, TRAFs appear to control the terminal phases of CD40-induced B cell differentiation. Although early B cell clonal expansion and early differentiation appear intact in the absence of TRAFs, GC formation, affinity maturation and long-lived humoral immunity are impaired without TRAF recruitment to CD40. The results we present here provide fresh insights into the functional domains of CD40 that control humoral immunity.
Methods
Construction of chimeric CD40. The oligonucleotides 5′-TTGGATCCATGGTTCGTCT GCCTCTGCAGT-3′ and 5′-ACAGGAATGACCAGCAGGGCTCTCAGCCGATCCTGG GGACCA-3′ were used to amplify the human CD40 ectodomain sequence; phCD40/GemT (Pullen, Danbury, CT) was used as a template. The oligonucleotides 5′-CAGGATCGGCT GAGAGCCCTGCTGGTCATTCCTGTCGT-3′ and 5′-TTATCAAAAGGTCAGCAAG CAGCCA-3′ were used to amplify the mouse cytoplasmic and transmembrane domain sequence that contained an NH2-terminal overlap with the human CD40 ectodomain sequence from a plasmid encoding murine CD40 (a gift of E. Clark, University of Washington, Seattle). These two PCR products were annealed, extended with Taq polymerase and ligated into pGem-T (Promega, Madison, WI) to generate ph-mCD40/GemT. The oligonucleotides 5′-GGTGAAAGCGAATTTCTAGACACCTGGAAC-3′ and 5′-GTTCCAGGTGTCTAGAAATTCGCTTTCACC-3′ were used to generate a silent mutation (underlined) that eliminated the EcoRI site in the mouse CD40 cytoplasmic domain; then the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to generate ph-mCD40/EcoKO/GemT. EcoRI sites were inserted at the 5′ and 3′ ends of the chimeric CD40 coding sequence by PCR to generate ph-mCD40/Eco+/GemT. Amino acid substitutions in the murine CD40 cytoplasmic domain were generated with the use of complementary primers that had the desired base changes and ph-mCD40/Eco+/GemT as a template; the QuikChange site-directed mutagenesis kit was used. Chimeric CD40 was subcloned via the EcoRI sites into vector pDOI-5 for expression under the control of an MHC class II promoter 16 . All plasmid constructs were verified by automated DNA sequencing. Immunoblots. Protein samples were separated by 12% PAGE with SDS. Proteins were transferred to nitrocellulose and membranes were blocked with 1% bovine serum albumin (BSA) and/or 5% milk in TBS with 0.05% Tween-20. Primary antibody incubations were done overnight at 4 ºC in blocking buffers that were recommended by the antibody suppliers. After washing, secondary antibody incubations were done over 30-min periods in the same blocking buffers. Blots were developed with SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL) and exposed to x-ray film.
B lymphocyte stimulation in vitro.
Red blood cell and T cell-depleted splenocytes, which consisted of ∼85% CD19 + cells, were collected from transgenic mice that had been killed first. For signaling assays, cells were cultured at 5×10 6 per ml for 3-30 min with various stimuli, then lysed in 1% lysis buffer with a mixture of protease and phosphatase inhibitors. Cellular debris was cleared from lysates by centrifugation at 14000g for 10 min before denaturation in gel-loading buffer that contained β-mercaptoethanol and SDS by boiling for 5 min. For biological readouts, cells were cultured at 2×10 6 per ml for 2-5 days. For the induction of surface markers, 2 days of culture in soluble CD154 was followed by washing cells into staining media with CD23-specific antibodies for staining. Affinity maturation. Mice were given intraperitoneal immunizations of 100 µg of NP36-KLH (molar ratio of hapten to KLH) emulsified in CFA. On days 15 and 68 after immunization, serum was collected from peripheral blood. Circulating antibodies were measured by an isotype-specific, antigen-specific ELISA. NP25-BSA was used to capture all antigenspecific Igs, whereas NP4-BSA was used to capture only high-affinity Igs. Captured antibodies were detected with enzyme-conjugated rabbit anti-IgG1. Data are mean±s.e.m. of three mice per group.
ELISPOT assay. Bone marrow anti-NP-specific IgG1a-secreting cells were enumerated by an NP-specific ELISPOT assay. Bone marrow-derived B cells were plated at 2.4×10 6 cells/well in NP-BSA-coated HA96 well plates (Millipore, Bedford, MA) and threefold serial dilutions were made before incubation. Plates were incubated for 5 h at 37 °C within a 5% CO2 incubator. After incubation, plates were washed in 1× PBS and 0.5% Tween in 1× PBS. Antibody-secreting cells were detected with biotinylated anti-mouse IgG1 followed by HRP-streptavidin (Amersham Life Sciences, Piscataway, NJ). ELISPOTS were developed by a chromagen substrate, AEC (Sigma, St. Louis, MO) in DMF (Fischer Scientific, Fair Lawn, NJ) and 0.1 M sodium acetate buffer at pH 4.8-5.0. Immediately before development of ELISPOTS, 3% H2O2 was added to chromagen substrate. ELISPOTS were enumerated via a dual-axis light-dissecting microscope.
GCs. Mice were given intraperitoneal immunizations with sheep erythrocytes without adjuvant. Ten days after immunization, mice were killed and spleens were sectioned for confocal microscopic analysis or T cell-depleted for flow cytometric analysis. GCs were characterized as GL7 + PNA + CD19 + B cells that stained near to CD4 + CD8 + T cell zones in the spleen. Flow cytometric profiles were gated on B220 + B cells.
Note: Supplementary information is available on the Nature Immunology website.
